Lack of tocilizumab effect on mortality in COVID19 patients

Off-label tocilizumab use in COVID-19 patients reflects concern for cytokine release syndrome. Comparison of matched COVID-19 pneumonia patients found elevated IL-6 levels correlated with mortality that did not change with tocilizumab administration. Correlating mortality with increased IL-6 doesn’t...

Descripción completa

Detalles Bibliográficos
Autores principales: Holt, Gregory E., Batra, Mayank, Murthi, Mukunthan, Kambali, Shweta, Santos, Kayo, Bastidas, Maria Virginia Perez, Asif, Huda, Haddadi, Sara, Arias, Sixto, Mirsaeidi, Mehdi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555891/
https://www.ncbi.nlm.nih.gov/pubmed/33051534
http://dx.doi.org/10.1038/s41598-020-74328-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555891/
https://www.ncbi.nlm.nih.gov/pubmed/33051534
http://dx.doi.org/10.1038/s41598-020-74328-x

Ejemplares similares